Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen Following Epigenetic Regeneration in Triple Negative Breast Cancer
NCT01194908Phase 2Terminated
- Sponsor
- Emory University
- Start
- Jul 2010
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat, decitabine in triple-negative metastatic breast cancer (mTNBC), sponsored by Emory University. Started Jul 2010; status: terminated.
02
Drugs
panobinostatdecitabine
03
Conditions
triple-negative metastatic breast cancer (mTNBC)
Beyond the preview
Go deeper on NCT01194908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01194908.